Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
CRISPR Therapeutics AG (CRSP) had Return on Tangible Equity of -6.77% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.46M |
|
$-122.93M |
|
-- |
|
$1.46M |
|
$131.71M |
|
$-130.25M |
|
$8.16M |
|
$-122.09M |
|
$-122.09M |
|
$-122.93M |
|
$-122.93M |
|
$-122.93M |
|
$-122.93M |
|
$-130.25M |
|
$-125.93M |
|
96.05M |
|
96.05M |
|
$-1.28 |
|
$-1.28 |
|
| Balance Sheet Financials | |
$2.45B |
|
$112.17M |
|
$277.46M |
|
$2.73B |
|
$136.29M |
|
$585.47M |
|
$774.98M |
|
$911.26M |
|
$1.81B |
|
$1.81B |
|
$1.81B |
|
96.39M |
|
| Cash Flow Statement Financials | |
$-108.90M |
|
$-410.74M |
|
$591.91M |
|
$359.08M |
|
$431.31M |
|
$72.24M |
|
$16.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.96 |
|
-- |
|
-- |
|
0.24 |
|
0.32 |
|
100.00% |
|
-8933.33% |
|
-8933.33% |
|
-- |
|
-8373.94% |
|
-8431.48% |
|
$-109.40M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-6.77% |
|
|
Return on Tangible Equity |
-6.77% |
-4.51% |
|
-5.12% |
|
$18.83 |
|
$-1.14 |
|
$-1.13 |
|